Asset Details
Do you wish to reserve the book?
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients
Do you wish to request the book?
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients
2025
Overview
Anti-SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) have been shown to have clinical benefits in treating high-risk patients with mild-moderate COVID-19. SARS-CoV-2 RNA in serum (RNAemia), is usually associated with severe disease and deaths. This study evaluates real-life data on the effectiveness of mAbs therapies against SARS-CoV-2 infections by different viral variants, particularly in the presence of RNAemia, focusing on clinical outcomes.
From March 2021 to May 2022, high-risk patients with PCR-confirmed mild-moderate COVID-19 were enrolled at the Clinic of Infectious Diseases, San Paolo Hospital in Milan. Patients received Bamlanivimab/Bamlanivimab + Etesevimab/Casirivimab + Imdevimab/Sotrovimab based on Agenzia Italiana del Farmaco (AIFA) guidelines and prevalent SARS-CoV-2 variants. Nasopharyngeal swabs (NPS) and plasma samples were collected at infusion (t0) and after 7 days (t1). NPS viral loads and RNAemia were quantified using RT-qPCR, and variant typing was conducted. Clinical outcomes were evaluated, including time to symptom resolution and adverse effects.
Among 176 enrolled patients, treatment efficacy was observed in 96.6% with a median time to symptom resolution of 12 days (IQR 10-19). Viral load significantly decreased in both NPS and plasma by day 7 post-treatment (p<0.001). At t0, RNAemia was present in 61.9% of patients and NPS viral loads were higher in patients with RNAemia (p=0.002). However, after treatment, no significant differences in viral loads and times to symptom resolution were noted between patients with and without RNAemia. Omicron-infected patients exhibited higher plasma viral loads compared to Alpha and Delta variants (p<0.001) and the presence of RNAemia was significantly associated with Omicron (p<0.001). Vaccinated patients achieved faster recovery regardless of variant type (p=0.001).
Early administration of anti-SARS-CoV-2 mAbs in high-risk patients significantly reduced viral loads in NPS and plasma and improved clinical outcomes. Despite the presence of RNAemia, these tailored mAb therapies led to favorable recovery times and minimal adverse effects.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Aged
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antibodies, Neutralizing - therapeutic use
/ Antiviral Agents - therapeutic use
/ COVID-19
/ Disease
/ Female
/ Humans
/ Kinases
/ Male
/ Mutation
/ Patients
/ Plasma
/ Proteins
/ Recovery
/ Risk
/ RNA
/ Severe acute respiratory syndrome coronavirus 2
/ Testing
